Clinical Trial Update: Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating short-course FOLFOX chemotherapy with either nivolumab or nivolumab plus radiation as first-line treatment for metastatic or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Gastroesophageal Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING